Pulmonary toxicity of mTOR inhibitors. Comparisons of two populations: Solid organ recipients and cancer patients

依维莫司 医学 PI3K/AKT/mTOR通路 mTOR抑制剂的发现与发展 西罗莫司 病态的 癌症 肺炎 内科学 回顾性队列研究 生物 生物化学 细胞凋亡
作者
S. Gendarme,Jean Pastré,Eliane M. Billaud,Laure Gibault,R. Guillemain,Stéphane Oudard,Jacques Médioni,A. Lillo-Lelouet,Dominique Israël‐Biet
出处
期刊:Therapie [Elsevier BV]
卷期号:78 (3): 267-278 被引量:1
标识
DOI:10.1016/j.therap.2022.05.008
摘要

Mammalian target of rapamycin (mTOR) inhibitors-associated pneumonitis (mTOR-IP) has long been described in solid organ recipients (T) patients but more recently in cancer (K) patients. Its overall characteristics have never been compared between these 2 populations. The aim of this study was to compare them in terms of presentation, severity and outcome in T and in K patients.We carried out a retrospective study in a single French tertiary center. Four databases were used to ensure the exhaustive collection of all mTOR-IP cases between 2001 and 2020. All clinical, biological, radiological, pathological and outcome data were reviewed.Thirty-nine patients with mTOR-IP were diagnosed during this period, 24T and 15K patients. The average dosage of everolimus and sirolimus was 2,65mg (±1,78) and 2,75mg (±0,96) in T patients, respectively, versus 8,75mg (±2,26) for everolimus in K patients. The overall prevalence of mTOR-IP was 6.4% with a median time of occurrence of 7 months [IQR 3-35 months]. mTOR-IP were significantly more frequent (P<0.001) and occurred earlier (P<0.001) in cancer patients. No clinical, functional, radiological, pathological nor outcome differences were otherwise observed between the 2 groups. Average everolimus blood levels at the time of mTOR-IP diagnosis were in the range of recommended therapeutic values.Our study shows that mTOR-IP is comparable in terms of presentation in T and in K patients but that it occurs significantly earlier after drug introduction in the latter. This raises questions as to the potential role of the higher doses used in K patients as well as that of co-treatments in the pathogeny of the disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Rao发布了新的文献求助10
1秒前
liuJX完成签到,获得积分10
1秒前
Jasper应助灰灰12138采纳,获得10
1秒前
可爱的函函应助哑牛采纳,获得30
2秒前
Akim应助迷人依白采纳,获得30
2秒前
3秒前
今后应助ff不吃芹菜采纳,获得10
3秒前
斑马发布了新的文献求助10
3秒前
wergou发布了新的文献求助10
4秒前
4秒前
4秒前
孙铭蕾发布了新的文献求助10
4秒前
王王发布了新的文献求助10
5秒前
鳕鱼完成签到,获得积分10
7秒前
bkagyin应助科研通管家采纳,获得10
8秒前
Jasper应助科研通管家采纳,获得10
8秒前
wanci应助阿治采纳,获得10
8秒前
Orange应助科研通管家采纳,获得10
8秒前
Rondab应助科研通管家采纳,获得20
8秒前
Orange应助科研通管家采纳,获得10
8秒前
中和皇极应助科研通管家采纳,获得10
8秒前
8秒前
Boboy发布了新的文献求助10
8秒前
vic303发布了新的文献求助10
8秒前
科研通AI2S应助科研通管家采纳,获得10
9秒前
李健应助科研通管家采纳,获得10
9秒前
科研通AI5应助科研通管家采纳,获得10
9秒前
9秒前
9秒前
9秒前
9秒前
9秒前
儒雅儒雅完成签到 ,获得积分10
9秒前
言庭兰玉完成签到,获得积分10
9秒前
ning发布了新的文献求助10
10秒前
10秒前
NeuroYue发布了新的文献求助10
10秒前
lingboxian完成签到,获得积分10
12秒前
打打应助Eeeee采纳,获得30
12秒前
嗯嗯完成签到 ,获得积分10
12秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Social Research Methods (4th Edition) by Maggie Walter (2019) 2390
A new approach to the extrapolation of accelerated life test data 1000
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4009871
求助须知:如何正确求助?哪些是违规求助? 3549812
关于积分的说明 11303839
捐赠科研通 3284342
什么是DOI,文献DOI怎么找? 1810591
邀请新用户注册赠送积分活动 886393
科研通“疑难数据库(出版商)”最低求助积分说明 811406